study of 130 children demonstrated primary HHV-6 infection in 40% by 12 months of age and in 77% by 24 months of age. Fever is the most common finding in children with HHV-6 primary infection. 5 HHV-6, along with another closely related beta herpesvirus HHV-7, is known as a roseolaviruse because upon primary infection, roseola occurs in approximately 20% of febrile children. Roseola is a self-limiting exanthematous disease characterized by a rash that usually begins on the trunk and spreads to the back, legs and neck and lasts approximately 1-2 days. 6 Seizures occur in a small subset of children who present with febrile symptoms. It is hypothesized that childhood febrile seizures lead to an increased risk of hippocampal sclerosis, which leads to an increased risk of mesial temporal sclerosis and temporal lobe epilepsy. There is currently a prospective, multicenter study of the long-term outcomes of prolonged febrile seizures in childhood, with the hypothesis of HHV-6B involvement. 7 There are two species of HHV-6, HHV-6A and HHV-6B, which share about 95% overall nucleotide identity. Some open reading frames, however, have less than 70% identity, 8 which likely accounts for the differential tropisms, drug susceptibilities, and disease associations that have led to their recent reclassification as distinct viruses. 9 Though the viral genome usually persists as an extrachromosomal episome, HHV-6 can also integrate into host cell chromosomes; chromosomally integrated HHV-6 is estimated at a prevalence of 0.6%-1% in the general population. 10 While HHV-6 often persists asymptomatically in immunocompetent individuals, it can cause severe disease upon reactivation in the context of immunosuppression. 11 In fact, HHV-6 was originally isolated from peripheral blood mononuclear cell (PBMC) cultures from patients with AIDS-associated lymphoproliferative disorders. HHV-6 reactivation occurs in nearly 50% of all bone marrow and 20-30% of all solid organ transplant recipients within several weeks post transplant and is also common among patients undergoing allogeneic or autologous hematopoietic stem cell transplants (HSCT). 12 The majority of posttransplant reactivation is reported to occur with HHV-6B. Viral reactivation can result in clinical symptoms ranging from fever and skin rash, to bone marrow suppression and encephalitis. 11 The association of HHV-6 with multiple sclerosis Neurotropism and perhaps even a CNS reservoir for HHV-6 has been suggested based on studies reporting viral DNA in the brains and CSF of MS patients and controls. Concomitant studies reported higher levels of HHV-6 expression in MS brains compared to control brains and greater levels of viral DNA and viral messenger RNA (mRNA) specifically in the demyelinated plaques. The observations of viral mRNA and protein expression in oligodendrocytes underscored the hypothesis of HHV-6 as a driver of MS pathology (reviewed in Leibovitch and Jacobson 13 ). Collectively, these studies demonstrated that while HHV-6 may be commensal in the normal brain, its replication and activity are enriched in the context of MS pathology. However, not all published studies agree with the conclusion of higher HHV-6 viral loads in MS versus control brains or in MS lesions versus normal appearing white matter areas. There are myriad technical reasons why some but not all studies will have positive findings; it is necessary to keep in mind that the absence of evidence is not in itself evidence of absence.
In addition to studies of the virus in CNS tissues, many studies have linked the detection of HHV-6, or an immune response to HHV-6, in the periphery of MS patients with clinically active disease, and these observations appear valid across geographically varied populations. Multiple studies report increased levels of HHV-6 antibodies in MS cohorts compared to controls. A 2012 study of a Tasmanian cohort found HHV-6 IgG titer to be a significant predictor of relapse risk and a 2014 study of a Spanish cohort found that decreased HHV-6 antibody titers correlated with fewer relapses and less disease progression (reviewed in Leibovitch and Jacobson 13 ).
Other serological studies have focused on the immune response to a specific portion of the virus, an approach that may provide functional insights into the role of HHV-6 in disease. A 2013 study examined antibodies to a latency-promoting protein, U94/REP, and found elevated IgG levels in Tunisian MS patients compared to controls; for eight patients with samples collected during relapsing and remitting phases, significantly higher titers were detected during relapses compared to remissions. 14 Elevated antibodies against a latencypromoting protein may be one mechanism leading to the increased viral levels observed across many MS cohorts, as several studies report an increase in serum viral DNA during relapses. 15, 16 Demonstrating an association between a ubiquitous agent and a clinical disorder Despite compelling human molecular and pathological studies that have associated HHV-6 with several CNS disorders, it has been difficult to prove causation in clinical disease. This is due to several factors, including (1) the ubiquity of HHV-6 in the general population, (2) observational studies often yield associative results that cannot demonstrate causation, and (3) there is no well-established animal model of HHV-6.
Interventional studies such as clinical trials are effective for demonstrating the involvement of an agent in a disorder, as the agent can be targeted and specific outcomes monitored and correlated with measurable clinical changes. However, to date, there is no effective, specific anti-HHV-6 intervention to employ in clinical trials of patients with MS or other HHV-6-associated CNS disorders.
In the absence of interventional studies, experimental studies to assess outcomes of infection present an alternative. Humans are the only known hosts of HHV-6, and the lack of an animal model has impeded mechanistic studies of viral pathogenesis, drug susceptibility, and proof-of-concept disease association studies. While not extensive, there have been recent efforts to investigate HHV-6 infection in various animal models, including transgenic and humanized mice and several nonhuman primate species. 17 Modeling HHV-6 as a trigger of neuroinflammatory disease Animal models of HHV-6 infection have been difficult to establish because rodents lack the HHV-6 receptor for cellular entry, the complement regulatory receptor CD46. 18 The common marmoset (Callithrix jacchus) is a small New World nonhuman primate that naturally expresses CD46 and is therefore susceptible to infection with HHV-6. Human and marmoset CD46 are conserved at the nucleotide level, supporting a rationale for experimental inoculations with HHV-6.
Marmosets are ideal models for studying the pathogenesis and host response to a human virus due to their genetic and immunologic proximity to humans, in addition to their broad behavioral range. 19 Marmosets have been infected with other human herpesviruses including varicella zoster virus (VZV), 20 Kaposi's sarcoma-associated herpesvirus (KSHV), 21 as well as non-herpesviruses such as dengue (DENV). 22 Moreover, marmosets are especially appropriate for the study of a virus like HHV-6, implicated in neurologic conditions, due to their lissencephalic brain, sharing similar anatomic organization and gray-to-white matter volume ratio with humans. 19, 23 Our laboratory has published work examining primary infections of HHV-6A and HHV-6B in the marmoset. 24 In our first study, we reported different biological responses to HHV-6A and HHV-6B, now classified as separate viral species. 9 Moreover, we demonstrated differences in immunologic and virologic outcomes when the same virus was administered intravenously or intranasally. 24 As HHV-6 is almost ubiquitously acquired in early childhood, it is difficult to determine its role in a disease like MS that often manifests in early adulthood. Therefore, in a more recent study, we examined the effects of HHV-6 on the subsequent development of an experimental neuroinflammatory disease, experimental autoimmune encephalomyelitis (EAE). EAE is a widely studied model of MS, in which animals are sensitized with white matter antigens to result in autoimmune inflammatory-mediated CNS demyelination. Marmoset EAE presents with more radiologic and pathologic similarities to MS compared to rodent EAE 25 and is considered to represent a preclinical translational bridge for developing MS therapeutics. 26 In this study, we administered HHV-6A or HHV-6B intranasally and several months later induced EAE. Given the hypotheses of viral involvement in MS, we hypothesized that virus-inoculated marmosets would exhibit a more aggressive EAE course compared to controls (manuscript in preparation).
HHV-6 inoculated marmosets remained asymptomatic throughout the period of viral inoculations, during which a subset mounted antiviral antibody responses and had detectable viral DNA in blood and saliva. Viral antigen was detected, though infrequently, in the brain of an intranasally inoculated marmoset. These data are reminiscent of findings in humans, in which infections are often acquired asymptomatically and the virus persists at low, but at times detectable, levels in blood, saliva, and CNS tissue.
Following EAE induction, the HHV-6 inoculated marmosets exhibited significantly accelerated clinical EAE compared to the uninfected control marmosets, with earlier symptom onset and reduced survival following the appearance of brain lesions. HHV-6 viral antigen was found to be upregulated in EAE brain lesions, which is similar to observations of enriched viral nucleic acids and antigens in MS lesions (reviewed in Leibovitch and Jacobson 13 ). In the marmoset study, HHV-6 antigen was found to colocalize with T cells. In humans, HHV-6 antigen has been found to colocalize with oligodendrocytes, lymphocytes, and glial cells. 27, 28 The virus inoculated but not control marmosets exhibited a peripheral expansion of interferon gamma-producing effector memory CD8 T cells that correlated with time post EAE induction. These data suggest that administering HHV-6 intranasally may have primed the differentiation of this proinflammatory subset and contributed to the accelerated EAE in these animals (manuscript in preparation).
Viral infections can set the stage for neuroinflammation
The marmoset data summarized above suggest that viruses like HHV-6 can prime the immune system and subsequently lead to the exacerbation of inflammatory-mediated disorders, including neuroinflammation. This is reminiscent of a hypothesis developed by Fujinami et al. 29 termed the fertile field hypothesis. This hypothesis weaves together the MS susceptibility factors of genetics (particularly major histocompatibility complex (MHC) alleles) and viral infections and importantly contextualizes viral infections as contributing factors rather than etiologic agents.
The fertile field hypothesis puts forth that infections can induce a heightened immunologic state, which in the presence of additional antigens (environmental, viral, or self) can lead to the expansion of autoreactive T cells. This expanded pool of autoreactive T cells can then develop into autoaggressive cells in the presence of additional antigens (environmental, viral, or self). This concept incorporates the idea of a threshold for autoimmunity, which is set in part by an individual's genetics, and is regulated by the quality and magnitude of infections and the host immune responses to those infections. 29 Clinical trials to validate the hypothesis of viral involvement in MS Ultimately, the only way to convincingly demonstrate the involvement of any exogenous agent in a disease is through controlled clinical trials using prophylactic or therapeutic means to specifically interfere with that agent. In neurologic disease, CNS penetrability is an important consideration. Currently, there is no HHV-6-specific antiviral drug or treatment, though the identification of such compounds, in addition to HHV-6 immunotherapy, remains active areas of study. Decades of work by our group and others provide rationale for the development of anti-HHV-6 interventions to be used in the setting of acute and chronic neuroinflammatory conditions like MS.
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